Bone Biologics (BBLGW) Short term Debt (2016 - 2017)
Bone Biologics (BBLGW) has disclosed Short term Debt for 2 consecutive years, with $12.9 million as the latest value for Q3 2017.
- Quarterly Short term Debt rose 43.33% to $12.9 million in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $12.9 million through Sep 2017, up 43.33% year-over-year, with the annual reading at $1.2 million for FY2016, N/A changed from the prior year.
- Short term Debt for Q3 2017 was $12.9 million at Bone Biologics, up from $12.2 million in the prior quarter.
- The five-year high for Short term Debt was $12.9 million in Q3 2017, with the low at $1.2 million in Q4 2016.